Landos Biopharma, Inc. (LABP)
|Net Income (ttm)||-22.31M|
Landos Biopharma, a Phase 2 biotech developing oral small molecule therapies for autoimmune diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Landos Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.
Landos Biopharma is a clinical-stage biopharmaceutical company developing novel, disease-specific oral therapeutic candidates designed to address the therapeutic gap in the current treatment paradigm for autoimmune diseases.. We believe the therapeutics we discover and develop, if approved, will have a significant impact on the quality of life of patients suffering from autoimmune diseases. While great strides have been made, existing approaches continue to leave patient needs unmet, due in part to significant safety concerns. Our core experti... [Read more...]
|IPO Date |
|Stock Exchange |
|Ticker Symbol |